Edi Truell leads financing of gene therapy start-up ViroCell Biologics

Edi Truell is backing a gene and cell therapy start-up and is seeking to lead a £100 million financing as part of his latest venture.

Virocell Biologics is positioning itself as a contract development and manufacturing organisation [CDMO] to supply viral vectors and gene-modified cells to academic and corporate clients for therapies entering clinical trials.

The veteran financier said that viral vectors, the delivery mechanism to get the gene therapies into cells, was an “amazing technology” that could tackle diseases such as cancer and epilepsy.

In the NewsFlorence BuchananEdi Truell, gene therapy, cell therapy, CDMO, UK CDMO, viral vector, viral vectors, AAV vectors, lentivirus vectors, ViroCell, The Times, Farzin Farzaneh, John W. Hadden II, Truell Conservaton Foundation, Danny Truell, Syncona